Sartorius Aktiengesellschaft/€SRT

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Sartorius Aktiengesellschaft

Sartorius Aktiengesellschaft is a German company engaged in the development, manufacturing, and distribution of laboratory equipment and bioprocess solutions. The company's core business is centered around two main segments: Bioprocess Solutions, which includes products for the production of biopharmaceuticals, such as filters, bags, and bioreactors, and Lab Products & Services, offering laboratory instruments like balances and pipettes for various research applications. Founded in 1870, Sartorius is headquartered in Göttingen, Germany, and maintains a global presence with operations in Europe, Asia, and the Americas. Its strategic positioning is reinforced by a strong focus on innovation and comprehensive product offerings catering to the biopharmaceutical industry. Competitive strengths include robust R&D capabilities and a well-integrated supply chain that supports rapid adaptation to industry demands. Sources: Sartorius Corporate Website, Annual Reports.

Ticker

€SRT

Primary listing

XETRA

Industry

Life Sciences Tools & Services

Employees

13,573

ISIN

DE0007165607

SRT Metrics

BasicAdvanced
€13B
-
-
1.24
€0.73
0.42%

Bulls say / Bears say

Sartorius reported a 6.5% increase in sales revenue for Q1 2025, reaching EUR 883 million, driven by strong demand in the Bioprocess Solutions division. (marketscreener.com)
The company's underlying EBITDA rose by 12.2% to EUR 263 million in Q1 2025, with a margin expansion to 29.8%, indicating improved operational efficiency. (marketscreener.com)
Analysts from AlphaValue/Baader Europe have a 'Positive' outlook on Sartorius, citing strong consumables demand in Q1 2025. (marketscreener.com)
JP Morgan expressed a cautious stance on Sartorius's Q1 2025 results, expecting underlying EBITDA to be 3% below consensus, leading to a 4% share price decline. (tradingview.com)
Sartorius issued a profit warning in July 2024, leading to a 10% drop in share price and raising concerns about future earnings visibility. (marketscreener.com)
Analysts have described 2025 as a 'black box' for Sartorius, indicating uncertainty and potential risks in the company's future performance. (marketscreener.com)
Data summarised monthly by Lightyear AI. Last updated on 1 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €SRT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs